期刊文献+

犀角地黄汤合消风散对慢性皮炎湿疹模型小鼠血清LTB4、LTC4水平的影响 被引量:5

Study on the Impact of Serum LTB,LTC4 Levels of Chronic Dermatitis and Eczema Mice Model Treated by XiJiaoDiHuang Decoction and XiaoFeng Powder
下载PDF
导出
摘要 目的:观察犀角地黄汤合消风散对慢性皮炎湿疹模型小鼠血清LTB4、LTC4水平的影响。方法:50只小鼠随机分为5组,致敏小鼠,实验组采用犀角地黄汤合消风散煎剂给药17天,末次激发后24h处死小鼠,使用酶联免疫吸附试验对小鼠血清LTB4、LTC4进行检测。结果:犀角地黄汤合消风散中药干预1、2组LTB4检测结果分别为0.282ng/ml、0.313ng/ml,与模型组相比有非常显著和明显的差异(P<0.001和P<0.05),LTC4检测结果中药干预组分别为1.509ng/ml、1.602ng/ml,与模型组比较显著的差异(P<0.01)。结论:犀角地黄汤合消风散对慢性皮炎湿疹模型小鼠血清LTB4、LTC4水平有显著的调节作用。 Objective:Inspection the impact of mouse Serum LTB4/LTC4 levels on XijiaoDiHuang Decoction and XiaoFeng Powder of mouse chronic dermatits and eczema model.Methods:50 mice were randomly divided into five groups,Sensitized mice,experimental group were treated with XiJiaoDiHuang Decoction and XiaoFeng powder administration for 17 days,the last challenge after the mice were sacrificed 24h,using enzyme-linked immunosorbent assay for serum LTB4,LTC4 for testing.Results:DiHuang Decoction and XiaoFeng powder's 1,2 intervention group LTB4 test results were 0.282 ng/ml,0.313ng/ml,compared with the model group,a very significant and obvious difference(P〈0.001 and P〈0.05),LTC4 test results of Chinese medicine in the intervention group were 1.509ng/ml.1.602ng/ml,with the model group were significantly different(P〈0.01).Conclusions:XiJiaoDiHuang Decoction and XiaoFeng Powder has a significant regulatory role on mouse model of chronic dermatitis and eczema Serum LTB4,LTC4 levels.
出处 《四川中医》 2010年第5期16-18,共3页 Journal of Sichuan of Traditional Chinese Medicine
关键词 小鼠 皮炎湿疹 LTB4 LTC4 Mice dermatitis eczema LTB4 LTC4
  • 相关文献

参考文献3

二级参考文献18

  • 1[1]Iversen L, Fogh K, Ziboh VA, et al. Leukotriene B4 formation during human neutrophil keratinocyte interactions: evidence for transformation of leukotriene A4 by putative keratinocyte leukotriene A4 hydrolase[J]. J Invest Dermatol, 1993, 100(3): 293-298.
  • 2[2]James JM, Kagey-Sobotka A, Sampson HA. Patients with severe atopic dermatitis have activated circulating basophils[J]. J Allergy Clin Immunol, 1993, 91(6): 1155-1162.
  • 3[3]Shichijo M, Ebisawa M, Miura K, et al. Relationship between histamine release and leukotrienes production from human basophils derived from atopic dermatitis donors[J]. Int Arch Allergy Immunol, 1995, 107(4): 587-591.
  • 4[4]Fogh K, Herlin T, Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations [J]. J Allergy Clin Immunol, 1989, 83(2 Pt 1): 450-455.
  • 5[5]Ruzicka T, Simmet T, Peskar BA, et al. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis[J]. J Invest Dermatol, 1986, 86(2): 105-108.
  • 6[6]Koro O, Furutani K, Hide M, et al. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis[J]. J Allergy Clin Immunol, 1999, 103(4): 663-670.
  • 7[7]Sansom JE, Taylor GW, Dollery CT, et al. Urinary leukotriene E4 levels in patients with atopic dermatitis [J]. Br J Dermatol,1997, 136(5): 790-791.
  • 8[8]Adamek-Guzik T, Guzik TJ, Czerniawska-Mysik G, et al. Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermtitis syndrome. Relation to clinical status[J]. Allergy,2002, 57(8): 732-736.
  • 9[9]Capella GL, Grigerio E, Altomare G. A randomized trial of leukotriene receptor antagonist montelukast in moderate -to -severe atopic dermtitis of adults[J].Eur J Dermatol, 2001,11(3): 209-213.
  • 10[10]Chari S, Clark-Loeser L, Shupack J, et al. A role for leukotriene antagonists in atopic dermatitis?[J]. Am J Clin Dermatol, 2001, 2(1): 1-6.

共引文献52

同被引文献56

引证文献5

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部